JP2016530228A - 乳癌細胞の増殖を阻害する酵素阻害剤、その製造方法およびその使用 - Google Patents
乳癌細胞の増殖を阻害する酵素阻害剤、その製造方法およびその使用 Download PDFInfo
- Publication number
- JP2016530228A JP2016530228A JP2016522895A JP2016522895A JP2016530228A JP 2016530228 A JP2016530228 A JP 2016530228A JP 2016522895 A JP2016522895 A JP 2016522895A JP 2016522895 A JP2016522895 A JP 2016522895A JP 2016530228 A JP2016530228 A JP 2016530228A
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- growth
- enzyme inhibitor
- alkyl
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
4−クロロ−α−カルボリン1当量を、還流冷却器およびガス排出部を備えた二口フラスコ中に装入し、かつ氷浴で冷却した。次いで塩化スルホン酸1.5mLを撹拌下にゆっくりと滴加した。添加の完了後、氷浴を除去し、かつこの混合物を、TLCにより出発物質が認められなくなるまで室温で撹拌した。その後、冷却下に余剰の塩化スルホン酸を加水分解した。沈殿した固体を濾別し、冷水で洗浄し、かつ乾燥させた。次いで、この固体をTHF25mL中に再懸濁させ、かつ当該アミン20当量を撹拌下に混合した。この混合物を、TLCにより出発物質が認められなくなるまで室温で撹拌し、その後、溶媒を減圧下に除去し、残留物を水と混合した。沈殿した残渣を濾別し、かつ乾燥させた。
Claims (3)
- 一般式
置換基X、YはCであるか、またはXはCであってYはNであるか、またはXはNであってYはCであり、
Zは、NHであり、
基R1は、Ph−3−または4−CONH−R3または4−ハロゲンまたは4−OBn、−CN、−Cl、−Br、−F(−ハロゲン)、−OH、−CH3、−OCH3、−OC2H5、−OBn(−Oアルキル)、−CF3、−NO2、−NH2、−NHCO−アルキル、−SCH3;
Ph−3−および4−CONH−R3または4−ハロゲンまたは4−OBn、−CN、−Cl、−Br、−F(−ハロゲン)、−OH、−CH3、−OCH3、−OC2H5(−Oアルキル)、−CF3、−NO2、−NH2、−NHCO−アルキル、−SCH3であり、
基R2は、Br(−ハロゲン)、NO2、NH2であり、
基R3は、H、Br(ハロゲン)、ヘテロアリール、NH2、NHR4、NO2、CN、COOR4、NHSO2R4、NHCOR4、NHCOOR4、NHCONHR4、COアルキル、SO2NHR4、NHCONR5R6、SO2NR5R6であり、
基R4は、アルキル、アミノアルキル、ピペラジノアルキル、N−モルホリノアルキル、ヒドロキシアルキルであり、
基R5、R6は、アルキル;−CH2−CH2−T−CH2−CH2−であり、
Tは、O、NH、NR4である]
の官能性ピリド縮合インドールおよびピリドピロールからなる、乳癌細胞の増殖を阻害する酵素阻害剤。 - 請求項1に記載の乳癌細胞の増殖を阻害する酵素阻害剤の製造方法であって、置換基X、YがCであり、かつZがNHである前記酵素阻害剤を、副生成物不含で高純度で位置選択的かつ定量的に製造することを特徴とする、前記方法。
- 請求項1に記載の乳癌細胞の増殖を阻害する酵素阻害剤において、前記乳癌細胞の増殖を阻害する酵素阻害剤が、BrkおよびErbB2の阻害剤として攻撃的な乳癌において相乗的な阻害活性を示し、かつ阻害剤耐性乳癌において選択的腫瘍細胞アポトーシス活性を示す酵素阻害剤として使用することができる、前記酵素阻害剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013010603.6A DE102013010603A1 (de) | 2013-06-26 | 2013-06-26 | Brustkrebszellwachstum-hemmende Enzyminhibitoren, Verfahren zu ihrer Herstellung sowie deren Verwendung |
PCT/IB2014/002141 WO2014207573A2 (de) | 2013-06-26 | 2014-08-21 | Brustkrebszellwachstum-hemmende enzyminhibitoren, verfahren zu ihrer herstellung sowie deren verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016530228A true JP2016530228A (ja) | 2016-09-29 |
Family
ID=51905309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016522895A Pending JP2016530228A (ja) | 2013-06-26 | 2014-08-21 | 乳癌細胞の増殖を阻害する酵素阻害剤、その製造方法およびその使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9901570B2 (ja) |
EP (1) | EP3110421A2 (ja) |
JP (1) | JP2016530228A (ja) |
DE (1) | DE102013010603A1 (ja) |
WO (1) | WO2014207573A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
US11773093B1 (en) * | 2023-01-19 | 2023-10-03 | King Faisal University | N-(pyrimido[2,3-b]indol-7-yl)acetamide compounds as antibacterial agents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008542433A (ja) * | 2005-06-09 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CDK−1インヒビターとしてのα−カルボリン |
JP2012501984A (ja) * | 2008-09-08 | 2012-01-26 | ウニヴェルシダ’デリ ストゥディ ディ ミラノ−ビコッカ | NPM−ALK、RETおよびBCR−ABLのα−カルボリン阻害剤 |
WO2013167730A1 (en) * | 2012-05-11 | 2013-11-14 | Universita' Degli Studi Di Milano - Bicocca | Alpha-carbolines for the treatment of cancer |
-
2013
- 2013-06-26 DE DE102013010603.6A patent/DE102013010603A1/de not_active Ceased
-
2014
- 2014-08-21 WO PCT/IB2014/002141 patent/WO2014207573A2/de active Application Filing
- 2014-08-21 JP JP2016522895A patent/JP2016530228A/ja active Pending
- 2014-08-21 US US14/900,366 patent/US9901570B2/en active Active
- 2014-08-21 EP EP14799883.5A patent/EP3110421A2/de not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008542433A (ja) * | 2005-06-09 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | CDK−1インヒビターとしてのα−カルボリン |
JP2012501984A (ja) * | 2008-09-08 | 2012-01-26 | ウニヴェルシダ’デリ ストゥディ ディ ミラノ−ビコッカ | NPM−ALK、RETおよびBCR−ABLのα−カルボリン阻害剤 |
WO2013167730A1 (en) * | 2012-05-11 | 2013-11-14 | Universita' Degli Studi Di Milano - Bicocca | Alpha-carbolines for the treatment of cancer |
Non-Patent Citations (3)
Title |
---|
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014), 24(8), 1948-1951, JPN6018017037, 2014, ISSN: 0003964082 * |
DEVELOPMENT OF NOVEL PROTEIN KINASE INHIBITORS AS POTEITIAL THERAPEUTICS FOR BREAST CANCER, JPN6018017035, 2014, ISSN: 0003964080 * |
MEDCHEMCOMM (2014), 5(5), 659-664, JPN6018017036, 2014, ISSN: 0003964081 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014207573A3 (de) | 2015-05-14 |
EP3110421A2 (de) | 2017-01-04 |
WO2014207573A2 (de) | 2014-12-31 |
US20160235723A1 (en) | 2016-08-18 |
DE102013010603A1 (de) | 2014-12-31 |
WO2014207573A8 (de) | 2015-03-26 |
US9901570B2 (en) | 2018-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3041563C (en) | Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12) | |
CN105263915B (zh) | 谷氨酰胺酶抑制剂及使用方法 | |
Liu et al. | Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents | |
CN104936954B (zh) | 化合物及其使用方法 | |
Wang et al. | Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents | |
JP6947651B2 (ja) | 4,6−ピリミジニレン誘導体およびこれらの使用 | |
WO2020088357A1 (zh) | 联苯类化合物、其中间体、制备方法、药物组合物及应用 | |
Wang et al. | Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors | |
Wu et al. | Synthesis and biological evaluation of novel 2-arylamino-3-(arylsulfonyl) quinoxalines as PI3Kα inhibitors | |
Wang et al. | Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors | |
CN108864079A (zh) | 一种三嗪化合物及其药学上可接受的盐 | |
JP2023533350A (ja) | 脳透過性btk又はher2阻害剤としての化合物およびその製造方法と応用 | |
WO2017189893A1 (en) | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases | |
CN106231900B (zh) | 化合物及其使用方法 | |
JP2023145547A (ja) | Cd73阻害剤、その製造方法と応用 | |
JP2016530228A (ja) | 乳癌細胞の増殖を阻害する酵素阻害剤、その製造方法およびその使用 | |
CN101717397B (zh) | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 | |
WO2019120237A1 (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途 | |
WO2020082817A1 (zh) | 肟基萘醌类化合物及其制备方法和用途 | |
US20190071410A1 (en) | 3-Phenyl-7-Hydroxy-Isocoumarins as Macrophage Migration Inhibitory Factor (MIF) Inhibitors | |
WO2020077944A1 (zh) | 嘌呤系列衍生物及其制备方法和用途 | |
CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
CN108947904B (zh) | 一种含有七元内酰胺环的化合物及其应用 | |
EP3027594B1 (en) | 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors | |
WO2019126357A1 (en) | Agents for treating cancer and methods for identifying said agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170808 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181015 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190128 |